

PRODUCT INFORMATION



(±)-WIN 55,212 (mesylate)

Item No. 10736

CAS Registry No.: 137795-17-6
Formal Name: [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, methanesulfonate

MF: C₂₇H₂₆N₂O₃ • CH₃SO₃H
FW: 522.6


Purity: ≥98%

UV/Vis.: λ_{max}: 220, 331 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(±)-WIN 55,212 (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the (±)-WIN 55,212 (mesylate) in the solvent of choice, which should be purged with an inert gas. (±)-WIN 55,212 (mesylate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of (±)-WIN 55,212 (mesylate) in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF.

(±)-WIN 55,212 (mesylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (±)-WIN 55,212 (mesylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. (±)-WIN 55,212 (mesylate) has a solubility of approximately 0.25 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

(±)-WIN 55,212 is a racemic mixture of the cannabinoid (CB) receptor 1 (CB₁) and CB₂ agonist (+)-WIN 55,212-2 (Item No. 10009023) and the CB₂ neutral antagonist (-)-WIN 55,212-3 (Item No. 12022).¹ It inhibits electrically induced contractions in mouse vas deferens preparations (IC₅₀ = 0.006 μM) and reduces prostaglandin (PG) synthesis by 35% in mouse brain microsomes when used at a concentration of 30 μM.² (±)-WIN 55,212 decreases acetylcholine-induced writhing in mice with an ED₅₀ value of 0.25 mg/kg. It induces hypolocomotion, analgesia, hypothermia, and catalepsy in mice (ED₅₀s = 1.09, 0.5, 3.01 and 6.8 mg/kg, respectively).³

References

1. Savinainen, J.R., Kokkola, T., Salo, O.M.H., *et al.* Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB₂ receptor. *Br. J. Pharmacol.* **145**(5), 636-645 (2005).
2. D'Ambra, T.E., Estep, K.G., Bell, M.R., *et al.* Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. *J. Med. Chem.* **35**(1), 124-135 (1992).
3. Fan, F., Compton, D.R., Ward, S., *et al.* Development of cross-tolerance between Δ⁹-tetrahydrocannabinol, CP 55,940 and WIN 55,212. *J. Pharmacol. Exp. Ther.* **271**(3), 1383-1390 (1994).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/20/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM